论文部分内容阅读
目的观察溃结灵方治疗溃疡性结肠炎(UC)患者的临床效果及作用机制。方法将80例UC患者随机分为治疗组和对照组各40例,治疗组给予溃结灵方每日1剂和柳氮磺吡啶片每次1.0g,每日2次,对照组仅给予柳氮磺吡啶片,两组均8周为1个疗程。观察两组患者的临床疗效,治疗前后检测DNA酶Ⅰ、Fascin蛋白的表达。结果治疗组临床有效率(92.5%)高于对照组(72.5%),差异有统计学意义(P<0.05);治疗组患者治疗前后DNA酶Ⅰ分别为(109.73±28.46)、(135.13±36.10)μg/L,对照组治疗前后分别为(106.50±27.54)、(120.03±27.72)μg/L,两组治疗后均较治疗前明显提高(P<0.05或P<0.01),治疗后组间比较差异亦有统计学意义(P<0.05);治疗组Fascin蛋白转阴性率为86.49%,对照组为66.67%,治疗组显著高于对照组(P<0.05)。结论溃结灵治疗UC疗效确切,并能明显提高UC患者DNA酶Ⅰ活性,使Fascin蛋白表达转阴。
Objective To observe the clinical effect and mechanism of “Kuijieling Decoction” in treating patients with ulcerative colitis (UC). Methods Eighty patients with UC were randomly divided into treatment group (40 cases) and control group (40 cases). The treatment group was treated with Kuijinling Decoction daily and sulfasalazine tablets 1.0g twice daily, and the control group was given only Liu Sulfasalazine tablets, two groups were 8 weeks for a course of treatment. The clinical curative effect of two groups was observed. The expression of DNase Ⅰ and Fascin protein was detected before and after treatment. Results The clinical effective rate (92.5%) in the treatment group was significantly higher than that in the control group (72.5%) (P <0.05). The DNase Ⅰ in the treatment group was (109.73 ± 28.46), (135.13 ± 36.10) ) μg / L before and after treatment in the control group were (106.50 ± 27.54) and (120.03 ± 27.72) μg / L before and after treatment, both groups were significantly higher than those before treatment (P <0.05 or P <0.01) The difference was statistically significant (P <0.05). The negative rate of Fascin protein in treatment group was 86.49%, while that in control group was 66.67%. The treatment group was significantly higher than that in control group (P <0.05). Conclusion UCJ is effective in treating UC and can significantly increase the activity of DNase Ⅰ in UC patients and make the expression of Fascin protein negative.